TenQ · Equity ReportCharts view ⇢  Fact sheet  2026-07-31

CrowdStrikeCRWD

$218.2B market cap

Classified by the SEC under prepackaged software.

$213.10-7.7% from 52-week high · delayed close as of 2026-09-04 · not investment advice
+104.1% vs S&P 500 (SPY) +20.3% over twelve months
$76.08$117.68$159.28$200.88$242.48Sep '25Nov '25Jan '26Apr '26Jun '26Sep '26
The verdict

CrowdStrike in 29 checks

CrowdStrike at a glance: how it scores on value, growth, quality, health, shareholder returns and trend. The fuller the shape, the stronger the company. Behind each axis are six pass-or-fail checks from its filings, spelled out in the chapters below. Point at an axis to see them.

VALUEGROWTHQUALITYHEALTHRETURNSTREND

A mixed picture - strengths and real weaknesses - 17 of 29 checks passed.

Advertisement
I

Value

not scored

What you pay today for what the business produces, measured against CRWD's own history and its peers, never a universal rule.

Not enough data to score this fairly - the checks below show exactly what's missing.

Why there's no score: EBITDA at or below zero, or unavailable; no multiple history; no positive 3-year earnings growth to compare against.
1152.5xno history
40.4xown 7-year median 5x
0.7%cash earned per $ of price
-whole-business multiple
Free cash flow yield

What cash return does the business throw off per dollar of market value?

0.7%FCF yield today

0.0%5.0%10%201920202021202220232024202520267-year median 4.8%FCF yield 0.7%

2026 = at the latest close (2026-09-04), over the trailing twelve months; earlier years are annual averages

At 0.7%, you get less cash per dollar of market value than the 7-year median of 4.8% - the market is charging more for the same cash.

What does “Value” actually mean?

Value asks what you pay for each dollar of earnings, sales or cash the business produces. A high multiple isn't automatically bad - fast growers earn theirs - but a price far above the company's own history means the market expects a lot to go right. We compare each multiple to the company's own past and to its sector, never to a universal rule.

How we scored it · 0 of 3 checks passed
Cheaper than its own history (earnings)no multiple history
Earnings yield beats a long bond (4%)0.1% vs 4.0%
Better cash yield than its own history0.7% vs 4.8%
Free cash flow yield above 3%0.7% vs 3.0%
Cheap on enterprise valueEBITDA at or below zero, or unavailable
Price isn't outrunning growthno positive 3-year earnings growth to compare against
II

Growth

●●●3/4

What the company has actually reported - is it selling more, and is more of it becoming profit?

Growing, but with caveats - revenue +24.3% over the last year.

+24.3%vs the year before
+29.0%compound annual
-net income growth
-compound annual
Revenue history

Revenue: is the business selling more than it used to?

0.00$2.0B$4.0B2017201820192020202120222023202420252026$5.4B

◌ 2026 = trailing twelve months to the latest filed quarter, not a full fiscal year

Revenue reached $4.8B in 2025, compounding +29% a year since 2022 though the pace has cooled. The trailing twelve months are already running at $5.4B, ahead of the last full year.

Profit history

Net income: how much of that revenue becomes profit?

$-200M0.002017201820192020202120222023$73M202420252026$46M

◌ 2026 = trailing twelve months to the latest filed quarter, not a full fiscal year

The company lost $161M in 2025, more than the $13M it lost the year before. The losses are widening - check the Health chapter for how long the cash lasts.

Growth rate

How fast is it growing, year by year?

+22%revenue growth, FY 2025

0.0%50%100%20182019202020212022202320242025Revenue growth 22%

Revenue grew +22% in 2025. Each point is one year's change against the year before.

Per-share growth

Revenue per share: is your slice growing as fast as the company?

$19.20revenue per share, FY 2025

0.0010.0020.002019202020212022202320242025202621.536.42

2026 = trailing twelve months to the latest filed quarter (2026-07-31), not a full fiscal year

Revenue per share reached $19.20 in 2025, compounding +26% a year against +29% for CRWD as a whole. Dilution absorbed about 3.1 points of that growth. Free cash flow per share stands at $5.23.

What does “Growth” actually mean?

Growth here is what the company has actually reported to the SEC - not a forecast. We look at the last year, the three-year pace, whether growth is speeding up or slowing down, and whether it's been consistent rather than one lucky year. Hatched bars are fourth quarters we derived from annual filings (companies file a full-year 10-K rather than a Q4 report).

How we scored it · 3 of 4 checks passed
Outgrew its sector last year24.3% vs 15.8% (sector 70th pct, n=404)
Sustained growth beats its sector (3 years)29.0% vs 17.6% (sector 70th pct, n=373)
Profits grew last yearloss-making in both years
Profit growth beats its peersearnings at or below zero at either end
Growth is speeding up, not slowing1y 24.3% vs 3y 29.0%
Grew per share, not just in total99.8% vs 0.0%
III

Quality

●●●●●●3/6

Whether the growth makes real money - margins, returns on capital, and whether profits turn into cash.

A solidly profitable business, though not exceptional against its sector.

75.2%kept after direct costs
-2.5%kept after running costs
0.9%profit on shareholders' money
-1.8%against a 10% cost of capital
4353%operating cash ÷ net income
Margins

Margins: of every $1 of sales, how much survives each cost layer?

-100%0.0%201720182019202020212022202320242025202675%-2.5%0.9%

2026 = trailing twelve months to the latest filed quarter (2026-07-31), not a full fiscal year

Operating margin widened 2 points to -6% since 2022. The bottom line is still negative: costs below the operating line eat what is left.

Earnings quality

Earnings quality: do the reported profits turn into real cash?

0.00$1.0B$2.0B2017201820192020202120222023202420252026$2.0B$46M

2026 = trailing twelve months to the latest filed quarter (2026-07-31), not a full fiscal year

Operating cash flow runs at 4353% of reported profit, so the earnings are more than backed by cash - depreciation and other non-cash charges are understating what the business actually collects.

Returns on capital

What does it earn on the money it uses?

-50%0.0%20172018201920202021202220232024202520260.9%0.4%-4.2%

2026 = trailing twelve months to the latest filed quarter (2026-07-31), not a full fiscal year

ROE of -4% on shareholders' capital (ROCE isn't meaningful for this business model).

Income waterfall

Where does each dollar of revenue actually go?

$4.8BRevenue 2025$3.6BGross profit$-293MOperating income$-161MNet income

Of $4.8B in sales, nothing reaches the bottom line - the journey from revenue to profit ends $161M underwater.

Cash conversion

How much of every sales dollar ends up as free cash?

-50%0.0%201720182019202035%20212022202320242025202630%

◌ 2026 = trailing twelve months to the latest filed quarter, not a full fiscal year

27 cents of every sales dollar became free cash in 2025, down 4 points since 2022.

Spending intensity

What does staying competitive cost, per dollar of sales?

0.0%20%40%20172018201920202021202220232024202520267.6%29%23%

2026 = trailing twelve months to the latest filed quarter (2026-07-31), not a full fiscal year

The biggest claim on each sales dollar is research and development, at 29% of revenue (stock compensation 23%, capital spending 6%).

Return on capital employed

Does CRWD earn more on its capital than that capital costs?

-50%0.0%2018201920202021202220232024202510% cost-of-capital lineReturn on capital -4.2%

CRWD's return on capital is negative at -4.2% in 2025. The capital in the business is not yet earning anything back.

What does “Quality” actually mean?

Quality asks whether the growth makes real money. Margins show how much of each sale survives costs; return on equity shows what shareholders earn on their capital; and the profit-to-cash comparison catches companies whose accounting profits never turn into actual cash.

How we scored it · 3 of 6 checks passed
Better gross margins than peers75.2% vs 74.4% (sector 70th pct, n=245)
Runs leaner than peers (operating margin)-2.5% vs 11.0% (sector 70th pct, n=398)
Actually profitableTTM net income $46M
Earns well on shareholders' money0.9% vs 13.3% (sector 70th pct, n=346)
Earns a real return on the capital it employs-1.8% vs 10.0%
Profits are cash, not accounting43.53 vs 0.80
IV

Health

●●●●●5/6

The balance sheet stress test: could CRWD survive a bad year?

A fortress balance sheet - CRWD can survive a very bad year.

0.15xborrowed vs owned
1.6xnear-term bills coverage
-5xearnings ÷ interest bill
$5.0Bcash plus short-term investments
Debt & cash

Could it handle its debt if things went wrong?

0.00$2.0B$4.0B20162017201820192020202120222023202420252026$746M$5.0B

The company holds $5.0B in cash against $746M of debt - a net-cash balance sheet, which means a bad year is an inconvenience rather than a threat.

Shareholders' equity

Is the company's own capital growing or shrinking?

0.00$2.5B$5.0B20162017201820192020202120222023202420252026$5.1B

The company's own capital grew from $2.3B in 2023 to $5.1B (+121%). The business is building book value rather than consuming it.

What does “Health” actually mean?

Health asks one question: can the business survive a bad year? We check whether near-term bills are covered, whether debt is modest and shrinking, whether earnings comfortably pay the interest, and - for loss-makers - how many years of cash are left at the current burn rate.

How we scored it · 5 of 6 checks passed
Comfortable near-term liquidity1.57 vs 1.50
Debt isn't dominating0.15 vs 1.00
Debt trending the right waydebt/equity 0.15 now vs 0.72 five years ago
Earnings cover the interest-4.99 vs 5.00
Converts sales to cash better than its sector37.4% vs 23.1% (sector 70th pct, n=410)
Self-fundingTTM free cash flow $1.6B
V

Shareholder returns

●●●●0/4

How much cash actually flows back to owners - dividends, buybacks, whether the share count truly falls, and whether what is handed back is affordable.

CRWD returns nothing to owners yet, and the share count keeps rising - every dollar stays in the business.

$0.00dividends plus buybacks
-last fiscal year
$0.00last fiscal year
$1.1Bdilutes the buybacks
+69.2%since 2019 (as reported)
Capital returned vs stock comp

How much goes back to shareholders - and how much leaks out as stock compensation?

0.00$100M2017201820192020

Stock compensation ($1.1B) flows out with nothing returned - the dilution is winning.

Dilution rate (split-adjusted)

How fast is your ownership being diluted - or concentrated?

0.0%20%40%202047%202120222023202420252.4%

2.4% more shares last year - your stake was diluted by that much.

Dilution against what it bought

CRWD has issued or retired shares - did shareholders end up better off?

02505002019202020212022202320242025169591

Both lines start at 100 in 2019, so the gap between them is what each share gained or lost. Share counts are split-adjusted.

CRWD issued +69% more shares from 2019 to 2025, but revenue per share still rose +491%. The dilution bought more growth than it cost existing holders.

Why compare buybacks with stock compensation?

A company can trumpet billions in buybacks while quietly issuing nearly as much stock to employees. What matters to you is the net effect: is the share count actually falling? If not, the 'return' is mostly recycling.

How we scored it · 0 of 4 checks passed
Share count isn't climbingshares up 7.5% over 3 years
Buybacks outpace the stock issued to staffno buybacks against $1.2B of stock compensation
Hands cash back to ownersno dividends and no buybacks in the last twelve months
Meaningful yield to owners (dividends and buybacks)0.00 returned, 0.0% of market value
Reliable payer, never cutno dividend in the last three years
Dividend growing ahead of inflationno dividend in the last three years
VI

Trend analysis

●●●●●●6/6

What the market is doing about all of the above. This is price behaviour, not a fact about the business - read it as the market's current opinion, scored on six checks like every other chapter. The market is the S&P 500, measured by the SPY ETF with dividends included, over 3 months (63 trading sessions) and 12 months (252).

The market agrees: the stock is in a healthy uptrend on every horizon.

+49.6%the long-term trend line
+27.0%S&P 500 (SPY): +4.7%
+106.7%S&P 500 (SPY): +20.0%
-7.7%drawdown from peak
Trend

How is CRWD's trend actually behaving right now?

Price chart loads as you scroll…

Chart by TradingView

CRWD is in a clear uptrend. The price is above the band where recent trading settled, and that band is still rising underneath it, so the floor keeps moving up. The last two weeks have rolled over even though the price is above where it stood a month ago, which is what losing steam looks like before it reaches the trend itself.

How the trend above is worked out

The trend read comes from the daily Ichimoku picture, a standard trend indicator, translated out of its jargon. It builds a band from the midpoints of the last 9, 26 and 52 sessions' highs and lows - in effect, the range where recent trading has settled - and draws that band 26 sessions into the future. Price above the band is an uptrend, below it a downtrend, inside it no trend. Because the band is drawn forward, the support for the next few weeks is already fixed and a change of its direction can be seen coming. We also compare the last two weeks against the last month, and today's price against where it stood a month ago. None of this says anything about the business; it describes the price only, and it is not advice. Where a check says 'the S&P 500', the comparison is with the SPY ETF including dividends, on the same adjusted basis as the stock's own price: short means 3 months, 63 trading sessions; long means 12 months, 252.

How we scored it · 6 of 6 checks passed
In an uptrend213.10 vs 142.49
Trend structure is healthy200.81 vs 142.49
Rising over 3 months27.0% vs 0.0%
Beating the S&P 500 over 3 months27.0% vs 4.7%
Beating the S&P 500 over 12 months106.7% vs 20.0%
Not in a deep hole-7.7% from its 52-week high
VII

Insider activity

informational

What the people running the company do with their own shares - reported to the SEC within two days, classified so pay-plumbing doesn't masquerade as conviction.

$0.00their own money
$12Moften pre-scheduled
60of the last filings
0grants · exercises · tax
Open-market flow

Are the people running it buying or selling with their own money?

$50M$25M0.00Jun '26Jul '26Aug '26Sep '26

No open-market buying, and $12M of selling across 4 months. Selling alone is a weak signal - much of it is pre-scheduled - but the absence of buying tells you no insider saw the price as a bargain.

The record

Who did what, exactly?

DateInsiderRoleTypeSharesValue
2026-09-03George KurtzPRESIDENT AND CEOSELL360$73,580
2026-09-03George KurtzPRESIDENT AND CEOSELL229$47,121
2026-09-03George KurtzPRESIDENT AND CEOSELL279$57,658
2026-09-03George KurtzPRESIDENT AND CEOSELL1,180$245,275
2026-09-03George KurtzPRESIDENT AND CEOSELL471$98,326
2026-09-03George KurtzPRESIDENT AND CEOSELL282$59,195
2026-09-03George KurtzPRESIDENT AND CEOSELL531$111,993
2026-09-03George KurtzPRESIDENT AND CEOSELL562$119,015
2026-09-03George KurtzPRESIDENT AND CEOSELL2,469$525,749
2026-09-03George KurtzPRESIDENT AND CEOSELL3,037$649,098
Why do the transaction types matter so much?

Most insider filings are not trades: stock grants, option exercises and tax withholding are how executives get paid, and gifts are estate planning. The signal lives in open-market transactions - a buy means an insider chose to spend their own cash on the stock. Sells are murkier: many are pre-scheduled 10b5-1 plans set months in advance. That's why the chart counts only open-market activity, and the table labels every row.

§

Recent filings

  • 10-Q Quarterly report
  • 10-Q Quarterly report
  • DEF 14A Proxy statement
  • 10-K Annual report
  • 10-Q Quarterly report
  • 10-Q Quarterly report
  • 10-Q Quarterly report
  • DEF 14A Proxy statement
The TenQ weekly brief is coming.One email a week: the charts that mattered, nothing else.